Lansforsakringar Fondforvaltning AB publ Acquires 17,438 Shares of Thermo Fisher Scientific Inc. $TMO

Lansforsakringar Fondforvaltning AB publ increased its stake in Thermo Fisher Scientific Inc. (NYSE:TMO) by 14.4% during the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 138,295 shares of the medical research company’s stock after purchasing an additional 17,438 shares during the period. Lansforsakringar Fondforvaltning AB publ’s holdings in Thermo Fisher Scientific were worth $67,976,000 as of its most recent SEC filing.

Several other hedge funds have also bought and sold shares of TMO. Assetmark Inc. increased its position in shares of Thermo Fisher Scientific by 22.9% in the fourth quarter. Assetmark Inc. now owns 37,654 shares of the medical research company’s stock valued at $21,819,000 after acquiring an additional 7,023 shares during the period. Mackenzie Financial Corp grew its stake in shares of Thermo Fisher Scientific by 29.4% in the third quarter. Mackenzie Financial Corp now owns 276,545 shares of the medical research company’s stock worth $134,130,000 after purchasing an additional 62,790 shares during the last quarter. North Dakota State Investment Board bought a new position in Thermo Fisher Scientific during the 4th quarter valued at approximately $7,505,000. Fisher Asset Management LLC lifted its holdings in Thermo Fisher Scientific by 1.2% in the 3rd quarter. Fisher Asset Management LLC now owns 2,721,101 shares of the medical research company’s stock worth $1,319,789,000 after buying an additional 31,298 shares during the period. Finally, Quadrant Capital Group LLC increased its stake in shares of Thermo Fisher Scientific by 30.9% during the third quarter. Quadrant Capital Group LLC now owns 14,277 shares of the medical research company’s stock valued at $6,924,000 after buying an additional 3,369 shares during the period. 89.23% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

Several research firms recently weighed in on TMO. Jefferies Financial Group upgraded shares of Thermo Fisher Scientific to a “strong-buy” rating in a report on Friday, April 24th. KeyCorp reaffirmed an “overweight” rating on shares of Thermo Fisher Scientific in a research note on Tuesday, May 26th. Piper Sandler assumed coverage on shares of Thermo Fisher Scientific in a research note on Thursday, June 11th. They issued a “neutral” rating and a $510.00 price target for the company. HSBC cut Thermo Fisher Scientific from a “buy” rating to a “hold” rating and cut their price objective for the company from $670.00 to $540.00 in a research report on Wednesday, June 3rd. Finally, Wall Street Zen lowered Thermo Fisher Scientific from a “buy” rating to a “hold” rating in a research report on Saturday, May 9th. Two analysts have rated the stock with a Strong Buy rating, eighteen have given a Buy rating and six have issued a Hold rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $605.09.

Insider Activity

In related news, COO Gianluca Pettiti sold 400 shares of the company’s stock in a transaction dated Monday, April 27th. The shares were sold at an average price of $462.66, for a total value of $185,064.00. Following the transaction, the chief operating officer owned 25,051 shares in the company, valued at $11,590,095.66. The trade was a 1.57% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 0.33% of the stock is currently owned by corporate insiders.

Thermo Fisher Scientific Trading Down 1.5%

NYSE:TMO opened at $505.09 on Tuesday. Thermo Fisher Scientific Inc. has a one year low of $401.45 and a one year high of $643.99. The company’s 50-day simple moving average is $473.86 and its 200 day simple moving average is $519.44. The firm has a market capitalization of $187.70 billion, a P/E ratio of 27.77, a PEG ratio of 2.27 and a beta of 0.88. The company has a debt-to-equity ratio of 0.77, a current ratio of 1.53 and a quick ratio of 1.15.

Thermo Fisher Scientific (NYSE:TMO) last released its earnings results on Thursday, April 23rd. The medical research company reported $5.44 earnings per share (EPS) for the quarter, beating the consensus estimate of $5.25 by $0.19. The firm had revenue of $11.01 billion during the quarter, compared to analyst estimates of $10.86 billion. Thermo Fisher Scientific had a net margin of 15.15% and a return on equity of 16.86%. The business’s revenue was up 6.2% on a year-over-year basis. During the same period last year, the business earned $5.15 earnings per share. Thermo Fisher Scientific has set its FY 2026 guidance at 24.640-25.120 EPS. As a group, analysts forecast that Thermo Fisher Scientific Inc. will post 24.85 EPS for the current fiscal year.

Thermo Fisher Scientific Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Wednesday, July 15th. Stockholders of record on Monday, June 15th will be issued a dividend of $0.47 per share. The ex-dividend date is Monday, June 15th. This represents a $1.88 annualized dividend and a dividend yield of 0.4%. Thermo Fisher Scientific’s dividend payout ratio (DPR) is presently 10.34%.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific (NYSE: TMO) is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.